Next 10 |
home / stock / zldpf / zldpf news
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...
2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...
2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...
2024-06-21 08:20:43 ET More on Zealand Pharma Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Zealand, Boehringer liver disease drug survodutide shows fibrosis improvement Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide ...
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Body weight reductions of up to a mean of 8.6% with high dose petrelintide after...
2024-06-07 10:21:55 ET More on Zealand Pharma Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Hist...
Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis News builds on previously announced primary e...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...